Latest news with #smallcapstocks
Yahoo
17 hours ago
- Business
- Yahoo
Unveiling 3 Undiscovered Gems in Europe with Strong Potential
In recent weeks, the European stock market has seen a modest rise, with the pan-European STOXX Europe 600 Index climbing 0.54% amid cautious optimism surrounding potential EU-U.S. trade agreements and steady interest rates from the European Central Bank. This environment of tentative optimism and stable economic indicators creates a fertile ground for identifying small-cap stocks that exhibit resilience and growth potential, making them intriguing prospects for investors seeking undiscovered gems in Europe. Top 10 Undiscovered Gems With Strong Fundamentals In Europe Name Debt To Equity Revenue Growth Earnings Growth Health Rating Caisse Régionale de Crédit Agricole Mutuel Brie Picardie Société coopérative 26.90% 4.14% 7.22% ★★★★★★ Martifer SGPS 102.88% -0.23% 7.16% ★★★★★★ Flügger group 30.11% 1.55% -30.01% ★★★★★☆ Decora 18.47% 11.59% 10.86% ★★★★★☆ Deutsche Balaton 4.58% -18.46% -16.14% ★★★★★☆ Viohalco 93.48% 11.98% 14.19% ★★★★☆☆ ABG Sundal Collier Holding 46.02% -6.02% -15.62% ★★★★☆☆ Evergent Investments 5.39% 9.41% 21.17% ★★★★☆☆ Darwin 3.03% 84.88% 5.63% ★★★★☆☆ Eurofins-Cerep 0.46% 6.80% 6.93% ★★★★☆☆ Click here to see the full list of 317 stocks from our European Undiscovered Gems With Strong Fundamentals screener. Below we spotlight a couple of our favorites from our exclusive screener. ChemoMetec Simply Wall St Value Rating: ★★★★★★ Overview: ChemoMetec A/S develops, produces, and sells analytical equipment for cell counting and analysis across the United States, Canada, Europe, and other international markets with a market capitalization of DKK8.99 billion. Operations: ChemoMetec generates revenue primarily from consumables (DKK208.76 million), instruments (DKK142.83 million), and services (DKK103.43 million). ChemoMetec, a nimble player in the Life Sciences sector, has shown robust earnings growth of 17.6% over the past year, outpacing the industry average of 13.2%. The company boasts high-quality earnings and maintains a healthy financial position with more cash than total debt. Over five years, its debt-to-equity ratio improved from 0.4% to 0.2%, reflecting prudent financial management. Recent guidance confirms expected revenue between DKK 470-490 million for 2024/25, indicating stable prospects ahead. With positive free cash flow and strong interest coverage, ChemoMetec seems poised for continued performance in its niche market space. Click here to discover the nuances of ChemoMetec with our detailed analytical health report. Learn about ChemoMetec's historical performance. Plejd Simply Wall St Value Rating: ★★★★★★ Overview: Plejd AB (publ) is a technology company that specializes in developing smart lighting control products and services across several countries, including Sweden, Norway, Finland, the Netherlands, and Germany; it has a market cap of approximately SEK7.47 billion. Operations: Plejd generates revenue primarily from its electronic security devices segment, amounting to SEK839.34 million. Plejd, a nimble player in the electrical industry, reported impressive earnings growth of 130% over the past year, outpacing the sector's -44.9%. With no debt on its books for five years and high-quality earnings, Plejd stands strong financially. Recent results show robust performance with net income reaching SEK 37 million for Q2 2025, up from SEK 19 million a year ago. Basic earnings per share improved to SEK 3.32 from SEK 1.69. However, significant insider selling in recent months might raise eyebrows despite forecasts suggesting a healthy annual growth rate of around 28%. Take a closer look at Plejd's potential here in our health report. Gain insights into Plejd's past trends and performance with our Past report. Bouvet Simply Wall St Value Rating: ★★★★★★ Overview: Bouvet ASA is an IT and digital communication consultancy firm serving both public and private sectors in Norway, Sweden, and internationally, with a market cap of NOK7.85 billion. Operations: Bouvet generates revenue primarily from IT consultancy services, amounting to NOK3.98 billion. The company's financial performance is highlighted by its net profit margin, which reflects the efficiency of its operations in converting revenue into profit. Bouvet, a nimble player in the IT sector, has shown robust financial health with earnings growing 12.5% annually over the past five years. Its price-to-earnings ratio of 19.7x is attractive compared to the industry average of 20.8x, indicating potential value for investors. The company is debt-free and boasts high-quality earnings, supported by its recent buyback of 1 million shares for NOK 73.88 million from February to June 2025. Additionally, Bouvet reported a net income increase to NOK 120.99 million in Q1 2025 from NOK 105.42 million last year, reflecting solid operational performance despite significant insider selling recently noted. Click to explore a detailed breakdown of our findings in Bouvet's health report. Evaluate Bouvet's historical performance by accessing our past performance report. Taking Advantage Embark on your investment journey to our 317 European Undiscovered Gems With Strong Fundamentals selection here. Invested in any of these stocks? Simplify your portfolio management with Simply Wall St and stay ahead with our alerts for any critical updates on your stocks. Simply Wall St is a revolutionary app designed for long-term stock investors, it's free and covers every market in the world. Seeking Other Investments? Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include CPSE:CHEMM NGM:PLEJD and OB:BOUV. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data
Yahoo
18 hours ago
- Business
- Yahoo
Iljin ElectricLtd And 2 Other Undiscovered Gems In Global Markets
As global markets continue to navigate a landscape shaped by favorable trade deals and record highs in key indices like the S&P 500 and Nasdaq Composite, investors are keenly observing the dynamics between value and growth stocks. With economic indicators showing robust growth in the services sector but challenges in manufacturing, identifying promising small-cap stocks becomes essential for those looking to capitalize on niche opportunities. In this context, discovering undervalued companies with strong fundamentals can offer potential avenues for diversification and growth amidst broader market trends. Top 10 Undiscovered Gems With Strong Fundamentals Globally Name Debt To Equity Revenue Growth Earnings Growth Health Rating S.A.S. Dragon Holdings 77.35% 3.64% 7.13% ★★★★★★ Indofood Agri Resources 30.05% 2.36% 41.87% ★★★★★★ Baazeem Trading 8.48% -2.02% -2.70% ★★★★★★ Saudi Azm for Communication and Information Technology 1.94% 16.33% 21.26% ★★★★★★ MOBI Industry 6.50% 5.60% 24.00% ★★★★★★ Sure Global Tech NA 11.95% 18.65% ★★★★★★ Etihad Atheeb Telecommunication 1.05% 36.24% 62.23% ★★★★★★ TSTE 36.22% 3.96% -8.49% ★★★★★☆ Darwin 3.03% 84.88% 5.63% ★★★★☆☆ National Environmental Recycling 69.43% 43.47% 32.77% ★★★★☆☆ Click here to see the full list of 3169 stocks from our Global Undiscovered Gems With Strong Fundamentals screener. Let's uncover some gems from our specialized screener. Iljin ElectricLtd Simply Wall St Value Rating: ★★★★★★ Overview: Iljin Electric Co.,Ltd specializes in the production of transmission and distribution power equipment, with a market cap of ₩1.97 trillion. Operations: Iljin Electric generates revenue primarily from its Wire and Power System segments, with the Wire segment contributing ₩1.42 trillion and the Power System segment adding ₩403.54 billion. The company has a market cap of approximately ₩1.97 trillion. Iljin Electric, a nimble player in the electrical sector, has been making waves with its robust earnings growth of 56% over the past year, far outpacing the industry average of 9%. The company seems to be on solid footing financially, boasting more cash than total debt and a significantly improved debt-to-equity ratio from 88.6% to 25.1% over five years. With interest payments covered by EBIT at an impressive 21.8 times and trading at nearly 17% below estimated fair value, Iljin might just be sparking interest among savvy investors seeking potential upside in this dynamic market space. Click here and access our complete health analysis report to understand the dynamics of Iljin ElectricLtd. Review our historical performance report to gain insights into Iljin ElectricLtd's's past performance. Shenzhen JPT Opto-Electronics Simply Wall St Value Rating: ★★★★★★ Overview: Shenzhen JPT Opto-Electronics Co., Ltd. focuses on the R&D, production, sales, and technical services of laser, intelligent equipment, and optical devices with a market cap of CN¥8.41 billion. Operations: JPT Opto-Electronics generates revenue primarily from its Computer Communications and Other Electronic Equipment segment, totaling CN¥1.54 billion. The company has a market cap of CN¥8.41 billion. Shenzhen JPT Opto-Electronics, a nimble player in the electronics industry, has shown impressive growth with earnings surging 37.7% over the past year, outpacing the industry's 2.8%. Their net income climbed to CNY 36.05 million from CNY 26.29 million a year ago, reflecting robust performance and high-quality earnings. The company's debt situation is favorable; its debt-to-equity ratio improved significantly from 8.3 to just 0.9 over five years, indicating prudent financial management. With revenue for Q1 hitting CNY 342.86 million compared to last year's CNY 255.73 million, future prospects appear promising as they continue on this upward trajectory. Click to explore a detailed breakdown of our findings in Shenzhen JPT Opto-Electronics' health report. Learn about Shenzhen JPT Opto-Electronics' historical performance. PharmaBlock Sciences (Nanjing) Simply Wall St Value Rating: ★★★★★☆ Overview: PharmaBlock Sciences (Nanjing), Inc. offers chemistry products and services for pharmaceutical research, development, and commercial production with a market cap of CN¥8.89 billion. Operations: PharmaBlock generates revenue primarily from its drug research and development and production-related business, amounting to CN¥1.77 billion. PharmaBlock Sciences, a nimble player in the pharmaceutical industry, has shown robust financial health with a net debt to equity ratio of 14.5%, which is considered satisfactory. The company boasts high-quality earnings and impressive interest coverage of 23.8 times its EBIT, indicating strong financial management. Over the past year, earnings have grown by 8.9%, outpacing the industry's -2.6% decline and highlighting its competitive edge in a challenging market environment. Trading at 56% below estimated fair value suggests potential for future appreciation, while forecasts indicate an annual growth rate of 12.61%. Dive into the specifics of PharmaBlock Sciences (Nanjing) here with our thorough health report. Examine PharmaBlock Sciences (Nanjing)'s past performance report to understand how it has performed in the past. Make It Happen Access the full spectrum of 3169 Global Undiscovered Gems With Strong Fundamentals by clicking on this link. Have you diversified into these companies? Leverage the power of Simply Wall St's portfolio to keep a close eye on market movements affecting your investments. Take control of your financial future using Simply Wall St, offering free, in-depth knowledge of international markets to every investor. Curious About Other Options? Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include KOSE:A103590 SHSE:688025 and SZSE:300725. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
2 days ago
- Business
- Yahoo
Undiscovered Asian Gems with Strong Potential In July 2025
As global markets reach new heights, buoyed by favorable trade deals and robust economic indicators, the Asian markets are also experiencing a wave of optimism. With recent developments in trade agreements and economic resilience, investors are increasingly looking towards small-cap stocks in Asia for their potential to capitalize on these dynamic conditions. In this environment, identifying promising companies involves assessing their ability to adapt to changing market landscapes while leveraging regional growth opportunities. Top 10 Undiscovered Gems With Strong Fundamentals In Asia Name Debt To Equity Revenue Growth Earnings Growth Health Rating AIC NA 26.88% 54.47% ★★★★★★ Toho 72.03% 6.01% 64.19% ★★★★★★ PSC 15.34% 1.17% 10.86% ★★★★★★ Nantong Guosheng Intelligence Technology Group NA 8.02% 1.71% ★★★★★★ HeXun Biosciences NA 74.95% 119.41% ★★★★★★ Zhejiang JW Precision MachineryLtd 12.36% 4.29% -22.66% ★★★★★★ Wholetech System Hitech 3.31% 15.16% 19.61% ★★★★★☆ Zhejiang Jinghua Laser TechnologyLtd 2.85% 4.02% -2.43% ★★★★★☆ Ningbo Henghe Precision IndustryLtd 66.02% 5.50% 23.91% ★★★★☆☆ Keli Motor Group 35.39% 9.99% -14.86% ★★★★☆☆ Click here to see the full list of 2601 stocks from our Asian Undiscovered Gems With Strong Fundamentals screener. We're going to check out a few of the best picks from our screener tool. Quechen Silicon Chemical Simply Wall St Value Rating: ★★★★★★ Overview: Quechen Silicon Chemical Co., Ltd. operates in the manufacture and supply of silica both in China and internationally, with a market capitalization of CN¥8.11 billion. Operations: Quechen Silicon Chemical generates revenue primarily from its Specialty Chemicals segment, amounting to CN¥2.21 billion. Quechen Silicon Chemical, a nimble player in the chemicals sector, has shown robust growth with earnings surging 23.4% over the past year, outpacing the industry's modest 4% rise. The firm is trading at a compelling value, sitting 33.4% below its estimated fair value. It boasts high-quality earnings and maintains an impressive debt-to-equity ratio that has shrunk from 9% to just 2.3% over five years. With strong free cash flow and profitability ensuring no worries about cash runway, Quechen appears well-positioned for continued growth with forecasts suggesting an annual earnings increase of nearly 11.82%. Click here and access our complete health analysis report to understand the dynamics of Quechen Silicon Chemical. Understand Quechen Silicon Chemical's track record by examining our Past report. HangzhouS MedTech Simply Wall St Value Rating: ★★★★★★ Overview: Hangzhou AGS MedTech Co., Ltd. specializes in the research, development, production, sale, and service of endoscopic surgery equipment and accessories in China with a market cap of approximately CN¥6.65 billion. Operations: HangzhouS MedTech generates revenue primarily from the sale of endoscopic surgery equipment and accessories. The company's net profit margin has shown a notable trend, reflecting its financial health and efficiency in managing costs relative to its revenue streams. With no debt over the past five years, HangzhouS MedTech showcases financial prudence, underscored by high-quality earnings. The company's earnings growth of 25.9% in the last year significantly outpaced the Medical Equipment industry average of -2.2%. Trading at a value 24.8% below its estimated fair value, it offers an attractive proposition compared to peers and industry standards. Levered free cash flow has shown a steady rise, reaching US$267.89 million recently, hinting at robust operational efficiency despite capital expenditures of US$41.16 million in the same period. Future growth prospects appear promising with forecasted annual earnings growth of 20.76%. Dive into the specifics of HangzhouS MedTech here with our thorough health report. Explore historical data to track HangzhouS MedTech's performance over time in our Past section. Medprin Regenerative Medical Technologies Simply Wall St Value Rating: ★★★★★★ Overview: Medprin Regenerative Medical Technologies Co., Ltd. is a company specializing in the development and manufacture of innovative regenerative medical products, with a market cap of CN¥4.96 billion. Operations: Medprin Regenerative Medical Technologies generates revenue through the development and manufacture of regenerative medical products. The company's financial performance is highlighted by a notable net profit margin, reflecting its efficiency in managing costs relative to its revenue streams. Medprin Regenerative Medical Technologies, a nimble player in the medical equipment sector, showcases impressive financial health with no debt and an earnings growth of 83.5% over the past year, outpacing the industry average of -2.2%. The company has transitioned to positive levered free cash flow recently, reaching CNY 102.39 million by mid-2025 from negative figures in prior years. Despite recent share price volatility, Medprin's strategic moves include a private placement at CNY 48.03 per share to raise funds for asset purchases and operational support, reflecting robust shareholder confidence and positioning it well for future endeavors. Delve into the full analysis health report here for a deeper understanding of Medprin Regenerative Medical Technologies. Gain insights into Medprin Regenerative Medical Technologies' past trends and performance with our Past report. Taking Advantage Take a closer look at our Asian Undiscovered Gems With Strong Fundamentals list of 2601 companies by clicking here. Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly. Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage. Curious About Other Options? Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SHSE:605183 SHSE:688581 and SZSE:301033. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
6 days ago
- Business
- Yahoo
CareCloud, Inc. (CCLD): A Bull Case Theory
This stock is one of several featured in our latest research. For more small-cap opportunities with asymmetric return potential, read our free article: 10 Promising SmallCap Stocks Under $1 Billion Market Cap. We came across a bullish thesis on CareCloud, Inc. (CCLD) on Undervalued and undercovered 's Substack by Hugh Navarro. In this article, we will summarize the bulls' thesis on CCLD. CareCloud, Inc. (CCLD)'s share was trading at $2.4 as of 16th July. CCLD's forward P/E was 8.28, respectively according to Yahoo Finance. A doctor utilizing a cloud-based healthcare platform to access patient records. CareCloud (Nasdaq: CCLD) presents a rare opportunity in the healthcare IT sector—a high-margin, recurring-revenue business trading at a deeply discounted valuation with an 18% free cash flow yield. Its core offering is a vertically integrated platform providing Revenue Cycle Management (RCM), Electronic Health Records (EHR), and Practice Management (PM) software to small and medium-sized medical practices. With 67% of revenue from RCM, CareCloud helps practices get paid faster and more efficiently, boasting a denial rate under 3% and up to 94% first-pass claims. The cloud-based system integrates billing, insurance checks, and analytics, differentiating itself with robotic automation and an in-house clearinghouse. Complementing this is a growing AI layer, cirrusAI, which powers real-time clinical note generation, chatbot support for staff, and automated appeals for denied claims. The company is aggressively expanding this AI infrastructure, aiming for 500 engineers by year-end, setting it up for long-term product superiority. Despite an 11% contribution from medical practice management, the real upside lies in the company's scalable tech and a consolidation strategy focused on acquiring customer bases from smaller, less efficient players. CareCloud also benefits from significant NOLs, insulating it from taxes for years. Past selling pressure due to a complex preferred-share structure has left shares undervalued, but a founder-led, 15%-insider-owned management team is now aligned for growth. The sector's rising complexity and demand for automation make CareCloud's solutions increasingly vital. With churn at just 5%, strong embedded pricing power, and multiple growth levers, the stock offers a compelling path to multi-bagger returns, potentially 5x from current levels. Previously we covered a on SANUWAVE Health, Inc. (SNWV) by @rationalformula in May 2025, which highlighted the company's turnaround story, recurring revenue from its FDA-cleared wound care device, and strong operational momentum. The company's stock price has appreciated by approximately 7% since our coverage. This is because the thesis played out with improving financials and execution. This is because demand for its consumables remains strong despite historical challenges. CareCloud author shares a similar view but emphasizes on software-driven efficiency and AI-powered automation as the growth engine in healthcare IT. CareCloud, Inc. (CCLD) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 3 hedge fund portfolios held CCLD at the end of the first quarter which was 3 in the previous quarter. While we acknowledge the potential of CCLD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
17-07-2025
- Business
- Yahoo
Undiscovered Gems In The US Market 3 Small Caps With Promising Potential
As the major U.S. stock indices, including the S&P 500 and Nasdaq, continue to hover near record highs amid a wave of earnings reports, investors are turning their attention to small-cap stocks for potential opportunities. In this environment of heightened market activity and economic indicators that influence smaller companies, identifying promising small-cap stocks can be key to uncovering hidden value in the market. Top 10 Undiscovered Gems With Strong Fundamentals In The United States Name Debt To Equity Revenue Growth Earnings Growth Health Rating FineMark Holdings 115.14% 2.19% -28.34% ★★★★★★ Senstar Technologies NA -20.82% 14.32% ★★★★★★ Metalpha Technology Holding NA 81.88% -4.97% ★★★★★★ Valhi 43.01% 1.55% -2.64% ★★★★★☆ China SXT Pharmaceuticals 64.25% -29.05% 10.33% ★★★★★☆ Gulf Island Fabrication 19.65% -2.17% 42.26% ★★★★★☆ Pure Cycle 5.02% 4.35% -2.25% ★★★★★☆ Solesence 82.42% 23.41% -1.04% ★★★★☆☆ Reitar Logtech Holdings 31.39% 231.46% 41.38% ★★★★☆☆ Vantage 6.72% -16.62% -15.47% ★★★★☆☆ Click here to see the full list of 280 stocks from our US Undiscovered Gems With Strong Fundamentals screener. Let's explore several standout options from the results in the screener. Citizens & Northern Simply Wall St Value Rating: ★★★★★☆ Overview: Citizens & Northern Corporation is a bank holding company for Citizens & Northern Bank, offering a range of banking and financial services to both individual and corporate clients, with a market cap of $301.52 million. Operations: Citizens & Northern generates revenue primarily through its Community Banking segment, which accounts for $108.11 million. The company's net profit margin is a key financial metric to consider when evaluating its profitability. Citizens & Northern, with total assets of US$2.6 billion and equity of US$281.8 million, is a bank with a strong footing in low-risk funding sources, primarily customer deposits making up 90% of liabilities. The bank's earnings grew by 16% last year, outpacing the industry average of 5.4%, and it trades at 46% below estimated fair value. However, its allowance for bad loans is insufficient at just 1.3%. Recent developments include an upcoming merger with Susquehanna Community Financial Inc., which could enhance its market position further while maintaining high-quality earnings performance. Navigate through the intricacies of Citizens & Northern with our comprehensive health report here. Review our historical performance report to gain insights into Citizens & Northern's's past performance. Waterstone Financial Simply Wall St Value Rating: ★★★★★★ Overview: Waterstone Financial, Inc. is a bank holding company for WaterStone Bank SSB, offering a range of financial services in southeastern Wisconsin with a market cap of $251.61 million. Operations: Waterstone Financial generates revenue primarily from its Mortgage Banking segment, contributing $78.43 million, and Community Banking segment, adding $55.20 million. The company's net profit margin reflects its financial efficiency in managing these operations. Waterstone Financial, with assets totaling US$2.2 billion and equity of US$341.4 million, is making waves in the financial sector. The company boasts a robust allowance for bad loans at 241%, well above industry norms, while maintaining a low non-performing loan ratio of 0.4%. Despite earnings declining by an average of 36% annually over five years, recent growth surged by 82%, outpacing the industry's 8%. With customer deposits comprising 75% of liabilities, funding remains low-risk. Recent board additions hint at strategic shifts as Waterstone continues its share buyback program, repurchasing over two million shares since May 2023 for US$32.5 million. Delve into the full analysis health report here for a deeper understanding of Waterstone Financial. Explore historical data to track Waterstone Financial's performance over time in our Past section. NL Industries Simply Wall St Value Rating: ★★★★★☆ Overview: NL Industries, Inc. operates in the component products industry across Europe, North America, the Asia Pacific, and internationally with a market capitalization of approximately $308.72 million. Operations: NL Industries generates revenue primarily from its component products segment, amounting to $148.20 million. The company's market capitalization stands at approximately $308.72 million. NL Industries, a compact player in the industry, recently reported first-quarter sales of US$40.27 million, up from US$37.97 million last year, though net income decreased to US$0.67 million from US$6.84 million. The company trades at 36% below its estimated fair value and boasts a significant earnings growth of 442% over the past year compared to the industry's 7%. With more cash than total debt and a reduced debt-to-equity ratio from 0.2 to 0.1 over five years, NL appears financially stable despite not being free cash flow positive currently. A quarterly dividend of $0.09 per share was also recently declared. Click here and access our complete health analysis report to understand the dynamics of NL Industries. Assess NL Industries' past performance with our detailed historical performance reports. Make It Happen Navigate through the entire inventory of 280 US Undiscovered Gems With Strong Fundamentals here. Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments. Maximize your investment potential with Simply Wall St, the comprehensive app that offers global market insights for free. Ready For A Different Approach? Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include CZNC WSBF and NL. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
